Receptors, not ligands. And our patents are for the compound, not the way it binds.
Our mixed-muscarinic-modulation has not been well defined. We have evidence of binding, but that family of receptors is very tricky, and the therapeutic value of activating and blocking them for neurodegenerative diseases is not established. A lot of clinical research shows that they potentiating cholinergic neuron signaling is not very helpful in its own (see donepezil). Our hope is that by also activating S1 (properly), there can be synergistic benefit.
News 
Market Data 
Discover 
